BLEEDnFIRE Therapeutics launches with non-dilutive funding
Summary
BLEEDnFIRE Therapeutics has launched as an early-stage Swiss biotech focused on differentiated first-in-class RNA therapies for rare bleeding disorders. The company says it secured non-dilutive funding from Innosuisse, Venture Kick, the Gebert Rüf Foundation Innobooster program, and Kickfund. The announcement positions the startup within the life sciences and biotech ecosystem rather than the broader consumer or hardware market. This makes the item relevant to readers tracking pharma and biotech company developments and financing activity.
Funding
Amount
None
Total raised
Date
May 27, 2026
Announcement date
Investors
Innosuisse, VentureKick
Lead investors
Company
-
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected